Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive

Arquivos de Neuro-Psiquiatria

Yara Dadalti Fragoso¹  Maria Fernanda Mendes¹  Walter Oleschko Arruda¹  Jefferson Becker¹  Joseph Bruno Bidin Brooks¹  Margarete De Jesus Carvalho¹  Elizabeth Regina Comini-frota¹  Renan Barros Domingues¹  Maria Lucia Brito Ferreira¹  Alessandro Finkelsztejn¹  Paulo Diniz Da Gama¹  Sidney Gomes¹  Marcus Vinicius Magno Goncalves¹  Damacio Ramon Kaimen-maciel¹  Rogerio De Rizo Morales¹  Andre Muniz¹  Heloisa Helena Ruocco¹  Pedro Rippel Salgado¹  Livia Brito Bezerra De Albuquerque¹  Rodrigo Assad Diniz Da Gama¹  Sergio Georgeto¹  Josiane Lopes¹  Celso Luis Silva Oliveira¹  Francisco Tomaz Meneses Oliveira¹  Juliana Safanelli¹  Patricia Correia De Oliveira Saldanha¹  Massaco Satomi¹ 

关键词: JC virus;    multifocal leukoencephalopathy;    multiple sclerosis;    natalizumab;    esclerose multipla;    natalizumabe;    JC virus;    leucoencefalopatia multifocal progressiva;   

DOI  :  10.1590/0004-282X20130121

来源: SciELO

【 摘 要 】

Objective Natalizumab is a new and efficient treatment for multiple sclerosis (MS). The risk of developing progressive multifocal leukoencephalopathy (PML) during the use of this drug has created the need for better comprehension of JC virus (JCV) infection. The objective of the present study was to assess the prevalence of JCV-DNA in Brazilian patients using natalizumab. Method Qualitative detection of the JCV in the serum was performed with real-time polymerase chain reaction (PCR). Results In a group of 168 patients with MS who were undergoing treatment with natalizumab, JCV-DNA was detectable in 86 (51.2%) patients. Discussion Data on JCV-DNA in Brazil add to the worldwide assessment of the prevalence of the JCV in MS patients requiring treatment with natalizumab.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License